PhotoPharmics Phase 2 Parkinson’s Disease
April 16, 2026
PhotoPharmics will be attending the American Academy of Neurology Annual Meeting (AAN) in Chicago, April 18-22. PhotoPharmics’ pivotal Phase 3 Light for Parkinson’s Disease clinical trial is in its final weeks, and topline results will likely be shared at the World Parkinson Congress in late May. This fully remote, randomized, double-blind, placebo-controlled study is evaluating Celeste®, an investigational photo-neuromodulation device, in individuals living with Parkinson’s disease.
If you’ll be at AAN, drop by the PhotoPharmics Booth, #3614.
Recent News
- Collaboration with Quest Diagnostics to expand kidneyintelX.dkd TM testing in the United States
- Utah Business Innovation Awards Summit Recap
- Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
- Co-Diagnostics Expands Vector Smart® Customer Reach with First International Installation in USAF Base
- Rep. Celeste Maloy Tours BIOS, Neurotech Innovation
- U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam for Pediatric Patients with Tourette Syndrome
